A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas
Stopped early · Phase 2
Conditions studied: Metastatic Melanoma
In brief
The purpose of this protocol is to determine whether autologous TIL infused in conjunction with systemic high-dose IL-2 after non-myeloablative chemotherapy with cyclophosphamide and fludarabine can cause consistent and durable objective responses in patients who have metastatic melanoma at the John Wayne Cancer Institute (JWCI).
Key facts
- Study ID
- NCT02375984
- Run by
- Saint John's Cancer Institute
- People needed
- 1
- Starts
- 2016-03-16
- Expected to finish
- 2017-06-01
- Last updated by the study team
- 2021-09-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- John Wayne Cancer Institute — Santa Monica, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.